Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SynCardia Artificial Heart Safety Should Be Confirmed Postmarket – Panel

This article was originally published in The Gray Sheet

Executive Summary

A postmarket study of SynCardia's CardioWest Total Artificial Heart (TAH) is needed to confirm that its safety remains in the same range as shown in the firm's non-randomized PMA study, according to FDA's Circulatory System Devices Panel
Advertisement

Related Content

Peer-Reviewed Study Placement Bodes Well For Artificial Heart Approval
Peer-Reviewed Study Placement Bodes Well For Artificial Heart Approval
CardioGenesis Prepares For New Trial Of Percutaneous Laser Angina Device
CardioGenesis Prepares For New Trial Of Percutaneous Laser Angina Device
People In Brief
People In Brief
Heart Failure Device Trials Lack Risk “Trade-Off” Data – CDRH’s Zuckerman
Heart Failure Device Trials Lack Risk “Trade-Off” Data – CDRH’s Zuckerman
Heart Failure Patient Conversion From LVAD To TAH Debated By Panel
Heart Failure Patient Conversion From LVAD To TAH Debated By Panel
Advertisement
UsernamePublicRestriction

Register

MT019959

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel